Compare · BTI vs CDXC
BTI vs CDXC
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and ChromaDex Corporation (CDXC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and CDXC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $130.30B, about 736.7x CDXC ($176.9M).
- BTI has hit the wire 9 times in the past 4 weeks while CDXC has been quiet.
- BTI has more recent analyst coverage (14 ratings vs 5 for CDXC).
- Company
- British American Tobacco Industries p.l.c.
- ChromaDex Corporation
- Price
- $59.70-0.05%
- $7.87-0.76%
- Market cap
- $130.30B
- $176.9M
- 1M return
- +2.80%
- -
- 1Y return
- +24.69%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- News (4w)
- 9
- 0
- Recent ratings
- 14
- 5
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
ChromaDex Corporation
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- Large owner Bt De Investments Inc. converted options into 95,281,277 shares and was granted 14,662,765 shares (SEC Form 4)
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest CDXC
- ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- ChromaDex to Present at the 37th Annual Roth Conference
- SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)
- ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- SEC Form 10-K filed by ChromaDex Corporation
- SEC Form 4 filed by Chief Executive Officer Fried Robert N
- ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025